2cureX Q4: Comments on the report

Research Note



Redeye gives its comments on the Q4 report published by 2cureX yesterday evening. Most important during the quarter was the finalized patient enrolment for its colorectal cancer study, which we expect to see results from relatively shortly.


Oscar Bergman

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.